Bayer Aktiengesellschaft (BAYRY): Price and Financial Metrics
GET POWR RATINGS... FREE!
BAYRY Stock Price Chart Interactive Chart >
BAYRY Price/Volume Stats
| Current price | $13.29 | 52-week high | $17.34 |
| Prev. close | $13.48 | 52-week low | $11.65 |
| Day low | $13.21 | Volume | 550,800 |
| Day high | $13.39 | Avg. volume | 446,589 |
| 50-day MA | $14.28 | Dividend yield | 3.09% |
| 200-day MA | $15.44 | Market Cap | 52.23B |
Bayer Aktiengesellschaft (BAYRY) Company Bio
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, and self-care solutions in the dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center at the University of Texas to develop cancer treatments; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies, supermarket and drugstore chains, online and other retailers, and hospitals, as well as directly to farmers. It has strategic research alliance with Kyoto University, Sensyne Health plc, and Atomwise Inc. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.
Latest BAYRY News From Around the Web
Below are the latest news stories about Bayer Aktiengesellschaft that investors may wish to consider to help them evaluate BAYRY as an investment opportunity.
BWXT Medical, Bayer AG Ink Agreement On Actinium-225BWX Technologies Inc's (NYSE: BWXT) subsidiary BWXT Medical Ltd. has agreed with Bayer AG (OTC: BAYRY) to develop Actinium-225 (Ac-225) supply and further partnering opportunities on finished products. The financial terms of the agreement were not disclosed. The companies to broaden their respective commercialization strategies for targeted radionuclide therapies (TRTs) and other products. Ac-225 is a radioisotope used in targeted alpha therapies (TATs), an emerging class of radionuclide therapy |
Andes Raises USD 15 Million in Series A Funding Co-Led by Leaps by Bayer and Cavallo VenturesLEVERKUSEN, Germany & EMERYVILLE, Calif., September 14, 2021--Leaps by Bayer, the impact investment arm of Bayer AG, today announced that it has co-led a USD 15 million Series A investment round in agriculture and biotechnology innovator, Andes, with Cavallo Ventures. Other new investors Builders VC, Germin8, Accelr8 and Wilson Sonsini participated, alongside existing investors KdT Ventures and Endurance. |
Bayer Unit Makes More Investments to Curb Synthetic Fertilizers(Bloomberg) -- Bayer AG just made its second investment in as many months in startups working to curb the use of synthetic fertilizers, a step that would help the agricultural industry -- a major polluter -- become more environmentally friendly.The industry giant, which owns agrochemical and biotechnology company Monsanto Co., said Tuesday one of its units co-lead a $15 million investment in Andes, a startup that treats seeds so plants can better draw nitrogen from the air instead of needing ene |
Automated Agricultural Helpers: Ripe for RobotsAgriculture must become more efficient: Robots and autonomous supertractors are one important solution. |
Bayer's (BAYRY) Chronic Cough Candidate Meets Efficacy GoalBayer (BAYRY) posts positive data from the phase IIb PAGANINI study which is evaluating its investigational candidate, eliapixant, in patients with refractory chronic cough. |
BAYRY Price Returns
| 1-mo | -4.04% |
| 3-mo | -14.92% |
| 6-mo | -14.81% |
| 1-year | -19.54% |
| 3-year | -35.44% |
| 5-year | -41.46% |
| YTD | -8.15% |
| 2020 | -24.50% |
| 2019 | 19.17% |
| 2018 | -42.40% |
| 2017 | 21.36% |
| 2016 | -15.03% |
BAYRY Dividends
| Ex-Dividend Date | Type | Payout Amount | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Loading social stream, please wait...